Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib maintenance versus placebo after first-line doxorubicin-based chemotherapy for high-grade uterine sarcoma
NL-OMON53073Phase 2Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in uterine sarcoma comparing Cabozantinib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival rate at 4 months. Started Oct 2015; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
uterine sarcoma
Beyond the preview
Go deeper on NL-OMON53073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53073.